Physician profile
Tri M Vo
NPI 1407907744
$18,448.78
in general payments reported to CMS, 2019-2025
27 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,141 · 2020: $2,530 · 2021: $2,828 · 2022: $1,661 · 2023: $2,397 · 2024: $1,388 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,226.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $1,652.52 | 2019-2024 | Vemlidy, Epclusa, Veklury |
| Amarin Pharma, INC. | $1,579.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,255.17 | 2019-2022 | |
| Abbott Laboratories | $1,162.62 | 2019-2023 | Gallant, Jot Dx, Confirm Rx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $798.05 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $703.24 | 2019-2024 | |
| Amgen INC. | $648.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $506.92 | 2019-2025 | Mounjaro |
| Allergan, INC. | $324.60 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $322.62 | 2023-2024 | |
| Abbvie INC. | $263.03 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $240.35 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $237.01 | 2024 | Inpefa |
| Glaxosmithkline, LLC. | $226.59 | 2020-2025 | Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $172.39 | 2019-2020 | |
| Alkermes, INC. | $130.00 | 2025 | Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $127.89 | 2022 | |
| Theratechnologies INC. | $125.01 | 2019 | |
| Pfizer INC. | $124.95 | 2019 | |
| Novo Nordisk INC | $119.21 | 2019 | |
| Intercept Pharmaceuticals, INC. | $116.55 | 2019 | |
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Esperion Therapeutics, INC. | $99.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.78 | 2019 | |
| Astellas Pharma US INC | $62.38 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $37.91 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.